CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade PTC Therapeutics Inc - PTCT CFD

50.04
7.54%
Market Trading Hours* (UTC) Open now
Closes on Monday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.20
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02354 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.02354%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001318 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001318%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 54.12
Open 50.89
1-Year Change 75.06%
Day's Range 47.58 - 50.89
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2025 54.12 0.17 0.32% 53.95 55.04 53.45
Mar 27, 2025 54.90 0.93 1.72% 53.97 55.90 53.96
Mar 26, 2025 55.19 -0.26 -0.47% 55.45 55.80 54.18
Mar 25, 2025 56.19 -0.25 -0.44% 56.44 56.79 55.45
Mar 24, 2025 56.93 -0.47 -0.82% 57.40 57.40 55.54
Mar 21, 2025 57.00 1.23 2.21% 55.77 57.20 55.36
Mar 20, 2025 56.57 0.55 0.98% 56.02 57.47 56.02
Mar 19, 2025 56.89 1.94 3.53% 54.95 57.30 54.95
Mar 18, 2025 55.42 -1.03 -1.82% 56.45 56.45 54.95
Mar 17, 2025 57.09 3.19 5.92% 53.90 58.22 53.90
Mar 14, 2025 54.44 1.40 2.64% 53.04 55.43 53.04
Mar 13, 2025 52.71 0.21 0.40% 52.50 54.53 52.50
Mar 12, 2025 53.50 0.94 1.79% 52.56 53.66 52.07
Mar 11, 2025 52.54 -0.34 -0.64% 52.88 53.01 50.65
Mar 10, 2025 52.39 0.51 0.98% 51.88 53.53 50.71
Mar 7, 2025 52.53 0.13 0.25% 52.40 53.61 51.56
Mar 6, 2025 52.72 1.75 3.43% 50.97 52.75 50.02
Mar 5, 2025 51.86 0.32 0.62% 51.54 52.35 50.41
Mar 4, 2025 51.72 -0.45 -0.86% 52.17 52.50 49.53
Mar 3, 2025 52.76 -1.69 -3.10% 54.45 55.40 52.45

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PTC Therapeutics Company profile

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, PTC Therapeutics, Inc. revenues increased 41% to $538.6M. Net loss increased 20% to $523.9M. Revenues reflect United States segment increase of 59% to $297M, Non-US segment increase of 24% to $241.6M. Higher net loss reflects Non-GAAP research and development increase of 11% to $487.1M (expense), Interest expense, net - Balancing value increase of 52% to $85.1M (expense).

Equity composition

Common Stock $0.001 Par, Shares auth 125M., 22,206,190 shares issd,. Insiders Owns approx.68.93%

Industry: Bio Therapeutic Drugs

100 Corporate Ct
SOUTH PLAINFIELD
NEW JERSEY 07080-2400
US

People also watch

Gold

3,123.14 Price
+1.210% 1D Chg, %
Long position overnight fee -0.0162%
Short position overnight fee 0.0080%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

19,215.60 Price
+0.230% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

83,491.10 Price
+1.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

ETH/USD

1,844.47 Price
+1.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading